.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The VRONI study has provided significant insights into the effectiveness of pediatric FH screening. Familial Hypercholesterolaemia (FH) is a common genetic disorder. It causes high LDL cholesterol from birth, leading to early cardiovascular disease. This study, conducted in Southern Germany, evaluated a two-step approach to identify affected children. Consequently, the findings support the call for universal screening programs to prevent premature heart disease.
The research team invited over 480 pediatricians in Bavaria to offer screening to children aged 5 to 15. Specifically, the process involved taking 0.2 mL of blood from a fingertip. If the low-density lipoprotein cholesterol (LDL-C) reached 3.36 mmol/L (130 mg/dL) or higher, the sample underwent genetic testing. This focused panel covered common variants and sequenced relevant genes. Furthermore, the study demonstrated that this biochemical-first approach is highly feasible in routine pediatric practice.
Out of 25,431 children screened, researchers found 1,689 with elevated LDL-C levels. Among these, they identified pathogenic variants in 283 individuals. Interestingly, the prevalence of FH-causing variants increased significantly with higher LDL-C concentrations. For instance, the positive rate was 78.6% in children with LDL-C above 5.17 mmol/L. After adjusting for bias, the predicted prevalence was 1 in 163. This figure is notably higher than the historical estimate of 1 in 250. Additionally, sequencing candidate genes proved more effective than using a focused variant panel alone.
These findings emphasize that early detection is crucial for managing FH. In India, where premature coronary artery disease is rising, universal screening could save many lives. Furthermore, the two-step method minimizes patient burden while ensuring high diagnostic accuracy. Therefore, pediatricians should consider biochemical screening as a reliable first step for identifying at-risk children.
Most guidelines, including the VRONI study, suggest screening children between ages 5 and 15. However, universal screening is often recommended between ages 9 and 11 to capture most cases before puberty affects lipid levels.
Genetic testing confirms the diagnosis of monogenic FH. It distinguishes genetic cases from multifactorial dyslipidemia. Moreover, identifying a specific variant allows for cascade screening of other family members.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional opinion. Readers should consult with a qualified healthcare professional for medical diagnosis or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Schmieder RS et al. Genetic screening of children for familial hypercholesterolaemia: the VRONI study. Eur Heart J. 2026 Jun 16. doi: undefined. PMID: 42301736.
Flyer JN et al. State-of-the-art review: The value of leveraging evidence and data (LEAD) in pediatric screening for familial hypercholesterolemia. Am J Prev Cardiol. 2025 Aug 22;23:101262.
Barde AK et al. Indian prevalence of familial hypercholesterolemia demystified by applying Dutch lipid clinic network criteria. Int J Adv Med. 2022 Nov;9(11).
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The VRONI study demonstrates the efficacy of a two-step pediatric FH screening approach. Finding a prevalence of 1 in 163, the study highlights the importance of early genetic and biochemical testing to prevent premature cardiovascular disease.
4 months ago
Depemokimab offers twice-yearly dosing for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, significantly cutting exacerbations and hospital admissions.
3 days back
A novel copper metal-organic framework hydrogel remodels the uterine microenvironment to stimulate robust endometrial regeneration, reduce intrauterine fibrosis, and restore reproductive fertility, offering a groundbreaking strategy for managing refractory endometrial damage and Asherman syndrome.
4 days back
New research reveals that non-ablative radiotherapy suppresses ventricular tachycardia by increasing conduction velocity via NaV1.5 upregulation and action potential prolongation. However, sustained sodium current elevation and depressed calcium handling highlight the need for careful clinical translation.
6 days back
A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
3 days back
A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
3 days back
